恶性星形细胞瘤采用尼莫司汀、替尼泊苷联合化疗的疗效分析

摘要

目的 探讨尼莫司汀、替尼泊苷联合治疗恶性星形细胞瘤的疗效.方法 对31例经病理诊断明确的恶性星形细胞瘤采用手术和放疗后采用尼莫司汀、替尼泊苷联合化疗的病例进行随访,同时将22例仪接受手术加放疗的恶性星形细胞瘤病例作为对照组.化疗采用尼莫司汀(宁得朗)2～3mg/kg,每疗程静脉给药1次,替尼泊苷300mg/m2,分成5d静脉给药,每6周为1个疗程,定期随访病人,采用Kaplan-Meier法统计随访结果 .结果 对照组的中位无进展生存时间为11.5个月,综合治疗组的中位无进展生存时间为13.5个月,综合治疗组病人中位无进展生存时间提高2个月.结论 尼莫司汀和替尼泊苷联合化疗方案对于恶性星形细胞瘤的治疗有一定疗效.%Objective To detect the effect of nimustine and teniposide on malignant astrocytoma.Method All the 31 cases of malignant astrocytoma were confirmed histologically,and underwent surgery,radiotherapy and nimustine & teniposide combination chemotherapy,22 cases of malignant astrocytoma patients who just undertook operation and radiotherapy as control group.Both of groups were followed up.Applied nimustine(nidran)2～3mg/kg by intravenous administration on the first day,teniposide 300mg/m2,by I.V.for 5 days.Every 6 weeks was defined as a cycle.Follow-up Was performed routinely and statistical analysis was done by using Kaplan-Meier method.Results The median progressive-free survival time of no chemotherapy group is 11.5 months,that of chemotherapy group is 13.5 months,the median progressive-free survival time of chemotherapy group increased 2 months.Condusiom The regimen of nimustine and teniposide is an effective chemotherapy for malignant astrocytoma.